Metformin Did Not Prevent Metabolic Syndrome During ADT but Improved Weight, Waist and HbA1c: Findings from the PRIME Phase 3 Trial
Highlight
– The PRIME randomized phase 3 trial found no statistically significant reduction in metabolic syndrome (MS) incidence at 18 months with metformin versus placebo in men initiating androgen deprivation therapy (ADT) for prostate cancer.
– Metformin produced modest but statistically significant improvements in body weight, waist circumference (at several time points), and hemoglobin A1c compared with placebo.
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.